You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)碘克沙醇注射液獲藥品註冊證書
格隆匯 12-09 20:00

格隆匯12月9日丨中國生物製藥(01177.HK)公告,集團開發的造影劑碘克沙醇注射液(商品名:沙貝安)的兩個規格(50ml:16g及100ml:32g)獲得中國國家藥品監督管理局頒發藥品註冊證書,且視同通過仿製藥質量和療效一致性評價。

碘克沙醇注射液是一種與血液等滲的X線診斷對比劑,具安全性高、對比度高、滲透壓低和人體毒性小等諸多優點,特別適用於脊髓造影,以及有造影劑反應高危因素病人的造影檢查。碘克沙醇注射液在神經和心血管系統、胸部、腹部、盆腔等器官病變的檢查中能起到提高病變檢出率和診斷鑑別的作用,受到國內外眾多臨牀指南和專家共識的認可和推薦。隨着全民醫保的深入,醫學影像技術的廣泛應用,國內對造影劑的需求旺盛,碘克沙醇注射液市場前景廣闊。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account